- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.10. | Debiopharm and NetTargets to identify synergistic drug combos for ADCs | ||
| 31.10. | Helex secures $3.5m to advance kidney disease therapies | ||
| 30.10. | Health Canada grants NOC for AstraZeneca's breast cancer therapy | ||
| 30.10. | FDA looks to simplify biosimilar development with new draft guidance | ||
| 30.10. | Novo Nordisk locks horns with Pfizer in late bid for Metsera | ||
| 30.10. | Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion | ||
| 30.10. | Dewpoint receives FDA orphan drug designation for DPTX3186 | ||
| 30.10. | Seres to obtain $3.6m from CARB-X for SER-155 development | ||
| 29.10. | Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis | ||
| 29.10. | Eli Lilly and NVIDIA to build pharma's "most powerful" supercomputer | ||
| 29.10. | CPHI 2025: time for European biopharma to double down on innovation | ||
| 29.10. | FDA rejects Regeneron's pre-filled Eylea HD syringes amid filling facility woes | ||
| 29.10. | GSK forges pact with Empirico for respiratory siRNA in $745m deal | ||
| 29.10. | Aldeyra reshuffles pipeline, culling asset despite Phase II success | ||
| 29.10. | Japan's MHLW grants orphan status to Kyowa and Orchard's MLD therapy | ||
| 29.10. | Lifecore and PolyPeptide link for US peptide manufacturing | ||
| 28.10. | GLP-1RA microdosing trend continues despite "anecdotal evidence" | ||
| 28.10. | Companies in all sectors 'should pay constant attention to geopolitics' - analysis | ||
| 28.10. | Novartis Q3: new drugs step up as generics squeeze Entresto | ||
| 28.10. | Hemab closes $157m in funding for bleeding disorder treatments | ||
| 28.10. | MSD receives FDA approval for Winrevair's updated indication | ||
| 27.10. | Organon CEO stands down amid contraceptive sales malpractice probe | ||
| 27.10. | Guardant and Zephyr AI pair up to advance cancer biomarker development | ||
| 27.10. | GSK targets Syndivia's prostate cancer ADC in £268m buy | ||
| 27.10. | Eli Lilly buys Adverum in eye disease gene therapy punt |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .